Agrawal, Yash N.; Fernandez-Martinez, Aranzazu; Gil-Gil, Miguel; Zielinski, Christoph; Ruiz-Borrego, Manuel; Ciruelos, Eva Maria; Munoz, Montserrat; Margeli, Mireia; Bermejo, Begona; Anton, Antonio; Kahan, Zsuzsanna; Csoeszi, Tibor; Alonso-Romero, Jose Luis; Garcia-Saenz, Jose angel; Sanchez-Rovira, Pedro; Alvarez, Elena; Chacon, Jose Ignacio; Gonzalez-Santiago, Santiago; Rodriguez, Cesar A.; Servitja, Sonia; Pfefferle, Adam D.; Herranz, Jesus; Liu, Yuan; Carey, Lisa A.; Romero-Camarero, Isabel; Caballero, Rosalia; Guerrero-Zotano, Angel; Perou, Charles M.; Martin, Miguel
(LIPPINCOTT WILLIAMS & WILKINS, 2025-07)
PURPOSE: For hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC), first-line cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) + endocrine therapy (ET) is ...